EXPLANATORY NOTE
The XBRL interactive data file included as an exhibit to this filing relates to the Supplement dated May 17, 2018 to the GMO Series Trust Prospectus, dated June 30, 2017, as supplemented, filed with the Securities and Exchange Commission on May 17, 2018 (SEC Accession No. 0001144204-18-029649) pursuant to Rule 497(e) under the Securities Act of 1933, as amended.
EXHIBIT INDEX
GMO SERIES TRUST
| Exhibit Ref. |
Title of Exhibit
|
| EX-101.DEF | XBRL Taxonomy Extension Definition Linkbase |
| EX-101.INS | XBRL Instance Document |
| EX-101.LAB | XBRL Taxonomy Extension Labels Linkbase |
| EX-101.PRE | XBRL Taxonomy Extension Presentation Linkbase |
| EX-101.SCH | XBRL Taxonomy Extension Schema Document |
Jun. 30, 2017 |
|---|
| GMO Benchmark-Free Allocation Series Fund |
GMO Benchmark-Free Allocation Series Fund |
GMO SERIES TRUST
Supplement dated May 17, 2018 to the
Effective May 18, 2018 (the “Effective Date”), the Board of Trustees of GMO Trust has approved the elimination of purchase premiums and redemption fees for certain series of GMO Trust, including, among others, (i) GMO Benchmark-Free Allocation Fund, GMO Global Asset Allocation Fund, GMO Global Equity Allocation Fund, GMO International Equity Allocation Fund, and GMO International Developed Equity Allocation Fund (each, an “Institutional Fund” in which corresponding series of GMO Series Trust invest) and (ii) GMO Implementation Fund and GMO Risk Premium Fund (each, an “Underlying Fund” in which certain Institutional Funds may invest). Accordingly, GMO Benchmark-Free Allocation Series Fund, GMO Global Asset Allocation Series Fund, GMO Global Equity Allocation Series Fund, GMO International Equity Allocation Series Fund, and GMO International Developed Equity Allocation Series Fund (the “Funds”) will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Institutional Funds and the Institutional Funds will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Underlying Funds, if any (which may impact the acquired fund fees and expenses of the Funds).
As of the Effective Date, the Prospectus is amended to remove the purchase premiums and redemption fees shown in the “Fees and expenses—Shareholder fees” table in the “Fund Summary” section for each of the Funds.
Additionally, the section appearing on page 122 of the Prospectus captioned “Supplemental Performance and Volatility Information Relating to Benchmark-Free Allocation Series Fund and SGM Major Markets Series Fund” is revised to clarify that the returns in the table in that section for GMO Benchmark-Free Allocation Fund reflect the purchase premiums and redemption fees charged by GMO Benchmark-Free Allocation Fund as of the periods ending December 31, 2016. |
| Label | Element | Value |
|---|---|---|
| Risk/Return: | rr_RiskReturnAbstract | |
| Registrant Name | dei_EntityRegistrantName | GMO Series Trust |
| Prospectus Date | rr_ProspectusDate | Jun. 30, 2017 |
| GMO Benchmark-Free Allocation Series Fund | ||
| Risk/Return: | rr_RiskReturnAbstract | |
| Risk/Return [Heading] | rr_RiskReturnHeading | GMO Benchmark-Free Allocation Series Fund |
| Supplement [Text Block] | gmost_SupplementTextBlock | GMO SERIES TRUST
Supplement dated May 17, 2018 to the
Effective May 18, 2018 (the “Effective Date”), the Board of Trustees of GMO Trust has approved the elimination of purchase premiums and redemption fees for certain series of GMO Trust, including, among others, (i) GMO Benchmark-Free Allocation Fund, GMO Global Asset Allocation Fund, GMO Global Equity Allocation Fund, GMO International Equity Allocation Fund, and GMO International Developed Equity Allocation Fund (each, an “Institutional Fund” in which corresponding series of GMO Series Trust invest) and (ii) GMO Implementation Fund and GMO Risk Premium Fund (each, an “Underlying Fund” in which certain Institutional Funds may invest). Accordingly, GMO Benchmark-Free Allocation Series Fund, GMO Global Asset Allocation Series Fund, GMO Global Equity Allocation Series Fund, GMO International Equity Allocation Series Fund, and GMO International Developed Equity Allocation Series Fund (the “Funds”) will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Institutional Funds and the Institutional Funds will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Underlying Funds, if any (which may impact the acquired fund fees and expenses of the Funds).
As of the Effective Date, the Prospectus is amended to remove the purchase premiums and redemption fees shown in the “Fees and expenses—Shareholder fees” table in the “Fund Summary” section for each of the Funds.
Additionally, the section appearing on page 122 of the Prospectus captioned “Supplemental Performance and Volatility Information Relating to Benchmark-Free Allocation Series Fund and SGM Major Markets Series Fund” is revised to clarify that the returns in the table in that section for GMO Benchmark-Free Allocation Fund reflect the purchase premiums and redemption fees charged by GMO Benchmark-Free Allocation Fund as of the periods ending December 31, 2016. |
Jun. 30, 2017 |
|---|
| GMO Global Asset Allocation Series Fund |
GMO Global Asset Allocation Series Fund |
GMO SERIES TRUST
Supplement dated May 17, 2018 to the
Effective May 18, 2018 (the “Effective Date”), the Board of Trustees of GMO Trust has approved the elimination of purchase premiums and redemption fees for certain series of GMO Trust, including, among others, (i) GMO Benchmark-Free Allocation Fund, GMO Global Asset Allocation Fund, GMO Global Equity Allocation Fund, GMO International Equity Allocation Fund, and GMO International Developed Equity Allocation Fund (each, an “Institutional Fund” in which corresponding series of GMO Series Trust invest) and (ii) GMO Implementation Fund and GMO Risk Premium Fund (each, an “Underlying Fund” in which certain Institutional Funds may invest). Accordingly, GMO Benchmark-Free Allocation Series Fund, GMO Global Asset Allocation Series Fund, GMO Global Equity Allocation Series Fund, GMO International Equity Allocation Series Fund, and GMO International Developed Equity Allocation Series Fund (the “Funds”) will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Institutional Funds and the Institutional Funds will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Underlying Funds, if any (which may impact the acquired fund fees and expenses of the Funds).
As of the Effective Date, the Prospectus is amended to remove the purchase premiums and redemption fees shown in the “Fees and expenses—Shareholder fees” table in the “Fund Summary” section for each of the Funds. |
| Label | Element | Value |
|---|---|---|
| Risk/Return: | rr_RiskReturnAbstract | |
| Registrant Name | dei_EntityRegistrantName | GMO Series Trust |
| Prospectus Date | rr_ProspectusDate | Jun. 30, 2017 |
| GMO Global Asset Allocation Series Fund | ||
| Risk/Return: | rr_RiskReturnAbstract | |
| Risk/Return [Heading] | rr_RiskReturnHeading | GMO Global Asset Allocation Series Fund |
| Supplement [Text Block] | gmost_SupplementTextBlock | GMO SERIES TRUST
Supplement dated May 17, 2018 to the
Effective May 18, 2018 (the “Effective Date”), the Board of Trustees of GMO Trust has approved the elimination of purchase premiums and redemption fees for certain series of GMO Trust, including, among others, (i) GMO Benchmark-Free Allocation Fund, GMO Global Asset Allocation Fund, GMO Global Equity Allocation Fund, GMO International Equity Allocation Fund, and GMO International Developed Equity Allocation Fund (each, an “Institutional Fund” in which corresponding series of GMO Series Trust invest) and (ii) GMO Implementation Fund and GMO Risk Premium Fund (each, an “Underlying Fund” in which certain Institutional Funds may invest). Accordingly, GMO Benchmark-Free Allocation Series Fund, GMO Global Asset Allocation Series Fund, GMO Global Equity Allocation Series Fund, GMO International Equity Allocation Series Fund, and GMO International Developed Equity Allocation Series Fund (the “Funds”) will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Institutional Funds and the Institutional Funds will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Underlying Funds, if any (which may impact the acquired fund fees and expenses of the Funds).
As of the Effective Date, the Prospectus is amended to remove the purchase premiums and redemption fees shown in the “Fees and expenses—Shareholder fees” table in the “Fund Summary” section for each of the Funds. |
Jun. 30, 2017 |
|---|
| GMO Global Equity Allocation Series Fund |
GMO Global Equity Allocation Series Fund |
GMO SERIES TRUST
Supplement dated May 17, 2018 to the
Effective May 18, 2018 (the “Effective Date”), the Board of Trustees of GMO Trust has approved the elimination of purchase premiums and redemption fees for certain series of GMO Trust, including, among others, (i) GMO Benchmark-Free Allocation Fund, GMO Global Asset Allocation Fund, GMO Global Equity Allocation Fund, GMO International Equity Allocation Fund, and GMO International Developed Equity Allocation Fund (each, an “Institutional Fund” in which corresponding series of GMO Series Trust invest) and (ii) GMO Implementation Fund and GMO Risk Premium Fund (each, an “Underlying Fund” in which certain Institutional Funds may invest). Accordingly, GMO Benchmark-Free Allocation Series Fund, GMO Global Asset Allocation Series Fund, GMO Global Equity Allocation Series Fund, GMO International Equity Allocation Series Fund, and GMO International Developed Equity Allocation Series Fund (the “Funds”) will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Institutional Funds and the Institutional Funds will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Underlying Funds, if any (which may impact the acquired fund fees and expenses of the Funds).
As of the Effective Date, the Prospectus is amended to remove the purchase premiums and redemption fees shown in the “Fees and expenses—Shareholder fees” table in the “Fund Summary” section for each of the Funds. |
| Label | Element | Value |
|---|---|---|
| Risk/Return: | rr_RiskReturnAbstract | |
| Registrant Name | dei_EntityRegistrantName | GMO Series Trust |
| Prospectus Date | rr_ProspectusDate | Jun. 30, 2017 |
| GMO Global Equity Allocation Series Fund | ||
| Risk/Return: | rr_RiskReturnAbstract | |
| Risk/Return [Heading] | rr_RiskReturnHeading | GMO Global Equity Allocation Series Fund |
| Supplement [Text Block] | gmost_SupplementTextBlock | GMO SERIES TRUST
Supplement dated May 17, 2018 to the
Effective May 18, 2018 (the “Effective Date”), the Board of Trustees of GMO Trust has approved the elimination of purchase premiums and redemption fees for certain series of GMO Trust, including, among others, (i) GMO Benchmark-Free Allocation Fund, GMO Global Asset Allocation Fund, GMO Global Equity Allocation Fund, GMO International Equity Allocation Fund, and GMO International Developed Equity Allocation Fund (each, an “Institutional Fund” in which corresponding series of GMO Series Trust invest) and (ii) GMO Implementation Fund and GMO Risk Premium Fund (each, an “Underlying Fund” in which certain Institutional Funds may invest). Accordingly, GMO Benchmark-Free Allocation Series Fund, GMO Global Asset Allocation Series Fund, GMO Global Equity Allocation Series Fund, GMO International Equity Allocation Series Fund, and GMO International Developed Equity Allocation Series Fund (the “Funds”) will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Institutional Funds and the Institutional Funds will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Underlying Funds, if any (which may impact the acquired fund fees and expenses of the Funds).
As of the Effective Date, the Prospectus is amended to remove the purchase premiums and redemption fees shown in the “Fees and expenses—Shareholder fees” table in the “Fund Summary” section for each of the Funds. |
Jun. 30, 2017 |
|---|
| GMO International Equity Allocation Series Fund |
GMO International Equity Allocation Series Fund |
GMO SERIES TRUST
Supplement dated May 17, 2018 to the
Effective May 18, 2018 (the “Effective Date”), the Board of Trustees of GMO Trust has approved the elimination of purchase premiums and redemption fees for certain series of GMO Trust, including, among others, (i) GMO Benchmark-Free Allocation Fund, GMO Global Asset Allocation Fund, GMO Global Equity Allocation Fund, GMO International Equity Allocation Fund, and GMO International Developed Equity Allocation Fund (each, an “Institutional Fund” in which corresponding series of GMO Series Trust invest) and (ii) GMO Implementation Fund and GMO Risk Premium Fund (each, an “Underlying Fund” in which certain Institutional Funds may invest). Accordingly, GMO Benchmark-Free Allocation Series Fund, GMO Global Asset Allocation Series Fund, GMO Global Equity Allocation Series Fund, GMO International Equity Allocation Series Fund, and GMO International Developed Equity Allocation Series Fund (the “Funds”) will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Institutional Funds and the Institutional Funds will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Underlying Funds, if any (which may impact the acquired fund fees and expenses of the Funds).
As of the Effective Date, the Prospectus is amended to remove the purchase premiums and redemption fees shown in the “Fees and expenses—Shareholder fees” table in the “Fund Summary” section for each of the Funds. |
| Label | Element | Value |
|---|---|---|
| Risk/Return: | rr_RiskReturnAbstract | |
| Registrant Name | dei_EntityRegistrantName | GMO Series Trust |
| Prospectus Date | rr_ProspectusDate | Jun. 30, 2017 |
| GMO International Equity Allocation Series Fund | ||
| Risk/Return: | rr_RiskReturnAbstract | |
| Risk/Return [Heading] | rr_RiskReturnHeading | GMO International Equity Allocation Series Fund |
| Supplement [Text Block] | gmost_SupplementTextBlock | GMO SERIES TRUST
Supplement dated May 17, 2018 to the
Effective May 18, 2018 (the “Effective Date”), the Board of Trustees of GMO Trust has approved the elimination of purchase premiums and redemption fees for certain series of GMO Trust, including, among others, (i) GMO Benchmark-Free Allocation Fund, GMO Global Asset Allocation Fund, GMO Global Equity Allocation Fund, GMO International Equity Allocation Fund, and GMO International Developed Equity Allocation Fund (each, an “Institutional Fund” in which corresponding series of GMO Series Trust invest) and (ii) GMO Implementation Fund and GMO Risk Premium Fund (each, an “Underlying Fund” in which certain Institutional Funds may invest). Accordingly, GMO Benchmark-Free Allocation Series Fund, GMO Global Asset Allocation Series Fund, GMO Global Equity Allocation Series Fund, GMO International Equity Allocation Series Fund, and GMO International Developed Equity Allocation Series Fund (the “Funds”) will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Institutional Funds and the Institutional Funds will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Underlying Funds, if any (which may impact the acquired fund fees and expenses of the Funds).
As of the Effective Date, the Prospectus is amended to remove the purchase premiums and redemption fees shown in the “Fees and expenses—Shareholder fees” table in the “Fund Summary” section for each of the Funds. |
Jun. 30, 2017 |
|---|
| GMO International Developed Equity Allocation Series Fund |
GMO International Developed Equity Allocation Series Fund |
GMO SERIES TRUST
Supplement dated May 17, 2018 to the
Effective May 18, 2018 (the “Effective Date”), the Board of Trustees of GMO Trust has approved the elimination of purchase premiums and redemption fees for certain series of GMO Trust, including, among others, (i) GMO Benchmark-Free Allocation Fund, GMO Global Asset Allocation Fund, GMO Global Equity Allocation Fund, GMO International Equity Allocation Fund, and GMO International Developed Equity Allocation Fund (each, an “Institutional Fund” in which corresponding series of GMO Series Trust invest) and (ii) GMO Implementation Fund and GMO Risk Premium Fund (each, an “Underlying Fund” in which certain Institutional Funds may invest). Accordingly, GMO Benchmark-Free Allocation Series Fund, GMO Global Asset Allocation Series Fund, GMO Global Equity Allocation Series Fund, GMO International Equity Allocation Series Fund, and GMO International Developed Equity Allocation Series Fund (the “Funds”) will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Institutional Funds and the Institutional Funds will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Underlying Funds, if any (which may impact the acquired fund fees and expenses of the Funds).
As of the Effective Date, the Prospectus is amended to remove the purchase premiums and redemption fees shown in the “Fees and expenses—Shareholder fees” table in the “Fund Summary” section for each of the Funds. |
| Label | Element | Value |
|---|---|---|
| Risk/Return: | rr_RiskReturnAbstract | |
| Registrant Name | dei_EntityRegistrantName | GMO Series Trust |
| Prospectus Date | rr_ProspectusDate | Jun. 30, 2017 |
| GMO International Developed Equity Allocation Series Fund | ||
| Risk/Return: | rr_RiskReturnAbstract | |
| Risk/Return [Heading] | rr_RiskReturnHeading | GMO International Developed Equity Allocation Series Fund |
| Supplement [Text Block] | gmost_SupplementTextBlock | GMO SERIES TRUST
Supplement dated May 17, 2018 to the
Effective May 18, 2018 (the “Effective Date”), the Board of Trustees of GMO Trust has approved the elimination of purchase premiums and redemption fees for certain series of GMO Trust, including, among others, (i) GMO Benchmark-Free Allocation Fund, GMO Global Asset Allocation Fund, GMO Global Equity Allocation Fund, GMO International Equity Allocation Fund, and GMO International Developed Equity Allocation Fund (each, an “Institutional Fund” in which corresponding series of GMO Series Trust invest) and (ii) GMO Implementation Fund and GMO Risk Premium Fund (each, an “Underlying Fund” in which certain Institutional Funds may invest). Accordingly, GMO Benchmark-Free Allocation Series Fund, GMO Global Asset Allocation Series Fund, GMO Global Equity Allocation Series Fund, GMO International Equity Allocation Series Fund, and GMO International Developed Equity Allocation Series Fund (the “Funds”) will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Institutional Funds and the Institutional Funds will no longer bear purchase premiums or redemption fees on subsequent purchases and sales of the Underlying Funds, if any (which may impact the acquired fund fees and expenses of the Funds).
As of the Effective Date, the Prospectus is amended to remove the purchase premiums and redemption fees shown in the “Fees and expenses—Shareholder fees” table in the “Fund Summary” section for each of the Funds. |
| Label | Element | Value |
|---|---|---|
| Risk/Return: | rr_RiskReturnAbstract | |
| Registrant Name | dei_EntityRegistrantName | GMO Series Trust |
| Prospectus Date | rr_ProspectusDate | Jun. 30, 2017 |
| Document Creation Date | dei_DocumentCreationDate | May 17, 2018 |